Pictor Named Proteomics Company of the Year in the 2026 BioTech Breakthrough Awards

Recognition follows a year of progress for Pictor’s targeted proteomics platform, including the PictImager launch, peer-reviewed research and expanding collaborations


CARLSBAD, Calif., and AUCKLAND, New Zealand – [Nov. X, 2026] – Pictor Holdings Inc. (“Pictor”), a targeted proteomics platform company founded in New Zealand, today announced it has been named Proteomics Company of the Year in the 2026 BioTech Breakthrough Awards. The recognition comes during a year of significant progress for Pictor, including the introduction of a new PictImager®, publication of peer-reviewed research and expansion of its commercial and research collaborations.

“This recognition reflects exceptional work by our team to make advanced protein analysis more practical and accessible to laboratories,” said Jamie Platt, PhD, Chief Executive Officer of Pictor. “We’ve focused on developing a platform that fits into established laboratory workflows while giving researchers and laboratory professionals new ways to measure multiple protein targets. It’s gratifying to see that work recognized as we continue expanding our partnerships and applications.”

A platform built to fit the laboratory

Pictor’s platform measures multiple protein targets in a single workflow using a familiar 96 well format in a PictArray ® assay, with a colorimetric readout quantified on the PictImager. The approach is designed to fit workflows and equipment many laboratories already use, without the specialized instrumentation required by some other platforms. Pictor introduced the new PictImager at ADLM 2026 in July, and the launch drew coverage from outlets including MLO, SelectScience, Clinical Lab Products and CAP TODAY.

Peer-Reviewed Research Supports Platform Development

The platform was recently benchmarked in a peer-reviewed, open-access study in the Journal of Immunological Methods. The study compared Pictor’s assay for extractable nuclear antigens (ENA) against two established commercial platforms, the Euroimmun ENA Line immunoassay and the Bio-Rad BioPlex 2200 ENA system, using 89 serum samples from patients with confirmed autoimmune disease. [OPTIONAL, confirm against the paper before use: Agreement across the three platforms was strongest for Jo-1 (100%), Sm and CENP-B (95%), with pairwise positive and negative percent agreement exceeding 85% for most of the autoantibody panel.] The full concordance data are published so laboratories can evaluate the results for themselves.

Growing research and commercial momentum

Beyond its technology development and published research, Pictor has continued expanding its research and commercial relationships in the United States and New Zealand, including work with DRL and Texas A&M University [confirm partnership wording with Pictor]. These activities reflect the company’s broader strategy to extend its targeted proteomics platform across laboratory, research and veterinary applications.

About Pictor

Pictor Holdings Inc. is a global targeted proteomic platform company headquartered in Carlsbad, California, with laboratory and commercial operations in New Zealand, Australia, and India. The company develops multi-analyte proteomic assay solutions for human and animal health research environments, enabling laboratories and biopharma partners to run more analytes, faster, at lower cost. Pictor’s IP portfolio includes 16 patents, five pending, and seven registered trademarks. For more information, visit www.pictorproteomics.com.

keyboard_arrow_up